We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Developing Next-Generation In Vitro Phenotypic Assays for Huntington’s Disease

Developing Next-Generation <i>In Vitro</i> Phenotypic Assays for Huntington’s Disease content piece image

Developing Next-Generation In Vitro Phenotypic Assays For Huntington’s Disease by Combining a Precision Reprogrammed hiPSC-Derived Disease Model With High-Density Microelectrode Arrays

There is currently no effective cure or treatment to slow down or stop the progression of Huntington's disease (HD). One reason for this is the lack of accurate and easy-to-use HD models that recapitulate the phenotypes and pathology seen in patients. Additionally, more advanced methods are required to record and analyze functional properties of cultured neurons over the entire maturation period, in order to gain insights into the underlying mechanisms of neurodegenerative diseases.

In this app note you will learn:

  • How high-density microelectrode arrays were used functionally to characterize a Huntington's disease model from bit.bio
  • How this Huntington's disease model forms an isogenic system that allows scientists to attribute experimental outcomes directly to a 50 CAG repeat expansion in the huntingtin gene
  • How the Huntington's disease model exhibits delayed neuronal network formation, decreased axonal branching and decreased spontaneous activity compared to the isogenic control